state cro industri construct ct gov
tuft csdd studi underscor cro valu proposit accord
recent studi tuft center studi drug develop
csdd largest control outsourc market rise
percentag point past seven year driven like greater
outsourc penetr share gain top leverag
broader offer geograph presenc csdd indic sponsor
layoff alongsid build pipelin well sustain biotech
demand continu drive greater outsourc penetr
posit cro univers previou studi note project
manag shorter cycl time studi initi day
faster establish relationship day new relationship overal
metric emphas valu proposit trial outsourc help
address grow complex expand scope clinic trial
intra-quart datapoint ct gov track activ close
studi regist clinicaltri gov databas locat sponsor
lead investig lead accord analysi
labcorp covance/chiltern activ ad trial
follow parexel syneo health
iqvia icon medpac medpac led way
average enrolle per newli regist trial total
patient analysi indic four new termin
averag six impact termin includ iqvia
medpac syneo
rais cro tp light rel construct datapoint
industri fundament rais target price iqvia
labcorp
icon plc
syneo charl river laboratori
broadli greater convict sustain strength
outsourc demand risk call includ tighten biotech fund
cancel demand shift
figur may partial snapshot total studi result search limit associ frequenc use acronym trial unrel
compani
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
print
report approach provid expect quarter
rel strong underli fundament backdrop continu favor larger global
iqvia covanc labcorp lh uniqu data capabl
augment expans geograph scale provid greater abil
address increasingli intern complex clinic trial
import note impact fulli lap allow greater
compar across industri though note backlog disclosur definit
ia hold outperform target price ia top cro
pick forecast ep line consensu includ revenu
growth bp oper margin expans forecast cro segment
revenu expand new busi award contribut net book-
to-bil quarter expect greater detail investor day
could hear greater disclosur vision cost save initi
expect implement long-term growth goal point focu
deploy revenu expect maintain posit bia
iqvia predic sustain strength outsourc demand consist
channel check iqv abil leverag global data asset uniqu
note march biogen inc discontinu four aducanumab trial
target alzheim diseas ad includ two global phase trial engag
emerg well associ phase trial prime evolv
cancel ad studi enrol particip aggreg possibl present
headwind iqvia due quintil disclos relationship april
inher occup hazard cancel financi
implic impact particular cancel disclos
would emphas singl custom account
syneo health outperform target price syneo remain
controversi name cro coverag univers
follow recent sec
investig earn delay forecast ep vs consensu
driven revenu growth partial off-set oper margin
compress bp note commerci segment experienc third
consecut sequenti improv top-line growth vs
albeit inher volatil segment estim commerci growth
clinic growth clinic btb quarter question
may surround sec investig suspect chang guidanc
call clinic top-line growth commerci growth
ebitda margin expans bp sum part analysi indic
market current ascrib de minimi valu commerci segment
revenu view unwarr point focu integr progress
underli demand commerci well clinic commerci btb
icon plc iclr outperform target price forecast ep
vs consensu predic organ constant currenc revenu
growth flat oper margin expect quarterli net book-to-bil
icon guidanc call revenu growth
million encompass million estim expect minim
chang guidanc also call ep vs estimate consensu
strong balanc sheet net cash million nt focu
area potenti interest includ late stage/pharmacovigil site network apac
central lab expans point focu capit deploy organ constant
health scienc outperform target price
forecast ep vs consensu driven revenu
growth ebitda margin expans bp assum net book-to-bil
includ net new project award y/i contribut
major partnership takeda continu strong book support
revenu growth ahead peer suggest increment market share gain
expect continu trade premium ep peer
point focu strateg partnership win guidanc symphoni integr hire
activ underli demand trend demand estimate revenu
medpac outperform target price forecast ep
vs consensu includ revenu growth
ebitda margin contract bp meaning sequenti deterior
previous disclos intern invest estim net book-
to-bil reflect medp conserv book polici rel peer
well continu roll-off million cancel disclos
confer call estimate expect continu benefit strong
underli fundament well exposur biotech custom base
continu repres faster grow segment market despit
suggest volatil segment weaker rfp flow surprisingli detail
call seemingli anomali rel construct broader industri
commentari point focu profit book rfp flow guidanc
labcorp lh outperform target price labcorp parent compani
covanc report earn april ep forecast
vs consensu reflect revenu growth ebitda margin contract
bp includ covanc segment revenu growth note
labcorp gave quarterli guidanc detail expect covanc growth
note expect quarter full-year guidanc growth due time
certain contract neg impact fx estim ttm net book-to-bil
vs cro segment gain traction moreov expect
cro leverag chiltern core strength bolster abil fsp/apac point
focu covanc launchpad progress new busi win relat combin
detail covanc btb sequenti improv clinic laboratori volum
charl river neutral target price expect ep
line consensu predic top-line growth
organ ebitda margin expans bp includ dsa revenu growth
guidanc impli revenu growth y/i hsd organ
growth modest oper margin improv moreov expect
revenu growth reflect discoveri safeti assess
research model servic manufactur support
ebitda margin expans bp reflect previous announc headwind
chang compens structur segment basi expect dsa
primari contributor margin improv rm manufactur
segment experi slight pressur crl niaid contract biolog
invest respect posit crl robust top-line growth
remain industri averag heed caution premium valuat
ep vs peer average point focu citoxlab closure/integr
fund commentari capit
accord recent studi march tuft univers center studi
drug develop leader analysi cro industri top largest
accord csdd control outsourc spend increas
seven year ago suggest top geograph scale broad
therapeut expertis take share
note previou survey project manag shorter cycl time
studi initi durat day faster establish cro relationship day
faster new relationship compar sponsor-run trial dynam
emphas valu proposit clinic trial outsourc help off-set grow
complex clinic trial expand scope studi also note sponsor
layoff alongsid build pipelin well sustain biotech demand continu
typic use cost plu price model cost relat clinic trial
bill client realiz margin top project cost iqvia
formerli quintil im introduc fix price model current employ
element fix price strategi across project
shift toward fix price model may pose challeng
limit data asset properli determin set achiev timelin take
account consider risk patient recruit bottleneck site identif
increasingli complex trial clinic trial design cost plu model provid cro
protect dynam though may also limit realiz margin project
hybrid outsourc model becom increasingli common result
dynam client becom reliant provid full-servic solut lead
strateg partnership longer stickier natur offer continu gain
favor amongst larg pharma custom retain certain function intern
choos outsourc other overal faster grow sub-seg
albeit lower margin rel full-servic result provid less work
compar full-servic offer sustain higher margin
compani data credit suiss estim lh figur incorpor cvd oper margin estim figur incorpor
dsa oper margin estim figur incorpor solut oper margin estim
figur compar compani analysi million excl per share valu
small/mid-s biotech mid-siz pharma larg pharma top biophama top biopharma smid biopharma last biotech global academic/govern new award pharmaceut sector come biotech sector award pharmaceut sector biotech sector breakdown state histor tradit clinic busi roughli larg pharma spec pharma/biotech disclosednot disclosedno disclosur novella unit focus small biotech estim l-msd revenueprxlnot disclosednot disclosedno disclosur biopharm unit said grow rapidli focus exclus emerg biotech though like less exposur biotech otherscvdnot disclosednot disclosedno disclosur previous larg pharma biotech last disclos cspriceupsid volrevenu cy average cy average cy average cy price-to-earnings cy ev/ebitda cy dividendtickerratingtargetdownsidepricecap research organizationsia river manufactur organizationswest pharmaceut group ag laboratorieslaboratori corp charl martineau pm univers toronto
trial complet part
compani remain key sourc growth
emerg
biotechnolog compani often lack financi resourc infrastructur conduct
develop process
autonom repres increas portion therapeut current
develop prolifer new complex therapeut immuno-
oncolog therapi diseas modifi capabl recent year help drive
continu invest biotechnolog compani broader capit market ventur
capit larg pharmaceut compani fuel demand outsourc research
develop servic view estim emerg mid-siz
biotechnolog compani repres much current drug pipelin
fund declin particularli tough comp y/i
metric indic d/outsourc demand particularli
above-averag exposur faster-grow small mid-siz biotech compani
 medpac note investor increasingli focus potenti inflect point
biotech fund robust biotech fund growth subsid follow sustain
strength fund acknowledg difficult comp alongsid
govern shutdown await clariti futur biotech fund metric could offer
relev read-through
accord bioworld biotech compani rais billion y/i vs
includ ipo follow-on financ public compani includ
loan bridg financ exercis warrant debt offer right offer standard
privat placement pipe financ institut offer regist stock
financ privat biotechnolog firm financ type public offer ipo follow-
on public debt offer privat financ declin respect
partial off-set increas public/oth highlight signific
deterior public offer fund note area may affect
govern shutdown earli shutdown necessit delay ipo
among factor
figur quarterli overal biotech fund includ public offer fund public
biotechnolog compani fund privat biotechnolog compani
note public offer includ ipo follow-on public/oth includ financ public compani includ loan bridg financ exercis warrant debt offer right
offer standard privat placement pipe financ institut offer regist stock privat biotech includ financ privat firm
multipl relev sourc fund virtual small mid-siz biotechnolog
compani summar
ventur capit fund accord data evaluatepharma ventur capit
fund declin vs importantli sourc fund
data captur limit scope transact thu multipl sourc like
provid comprehens view broader industri trend
biotech capit market accord bioworld fund public offer
includ ipo follow-on declin billion compar
billion figur financ public compani increas
billion versu billion see figur financ privat biotech
meanwhil fell billion biotech ipo
larg pharma academia -- also sourc fund contribut
larger pharma conting also repres underappreci sourc fund
view biotech fund stem licens deal royalti stream
partnership mileston payment importantli pharmaceut compani
increasingli seek bulk oppos ration pipelin
experienc major pharmaceut merger time-frame larger
pharmaceut compani remain key sourc fund small/mid-s biotech
compani inher insul broader capit market activ
compani grown critic drug develop process
accord tuft csdd sinc larg pharma spent billion purchas
biotechspublic/otherpubl growth tough comp charl martineau pm univers toronto
figur monthli overal biotech fund includ public offer fund public biotechnolog
compani fund privat biotechnolog compani
note public offer includ ipo follow-on public/oth includ financ public compani includ loan bridg financ exercis warrant debt offer right
offer standard privat placement pipe financ institut offer regist stock privat biotech includ financ privat firm
break sourc fund
figur public offer biotech compani includ ipo follow-on quarterli
biotechspublic/otherpubl sequenti growth charl martineau pm univers toronto
figur financ public biotechnolog compani quarterli
includ loan bridg financ exercis warrant debt offer right offer standard privat placement
pipe financ institut offer regist stock
figur fund privat biotechnolog compani quarterli
charl martineau pm univers toronto figur ipo fund healthcar compani quarterli
note differ sourc bioworld data exclud siemen healthin billion ipo
figur vc fund healthcar compani quarterli
note differ sourc bioworld data
year-over-year growth y/i charl martineau pm univers toronto figur biotechnolog ipo
note data use multipl sourc may use differ threshold inclus thu data use indic broad trend
figur estim biotech exposur cro
small/mid-s biotech mid-siz pharma larg pharma top biophama top biopharma smid biopharma last biotech global academic/govern new award pharmaceut sector come biotech sector award pharmaceut sector biotech sector breakdown state histor tradit clinic busi roughli larg pharma spec pharma/biotech iqvnot disclosednot disclosedno disclosur novella unit focus small biotech estim l-msd revenueprxlnot disclosednot disclosedno disclosur biopharm unit said grow rapidli focus exclus emerg biotech though like less exposur biotech otherscvdnot disclosednot disclosedno disclosur previous larg pharma biotech last disclos charl martineau pm univers toronto
compani data credit suiss estim iqvia mix cs estim mix iclr mix cs estim
disclosur prxl revenu mix cs estim mix cs estim work
exposur cro estim total revenu
compani data credit suiss estim
grow faster market all-import growth
driver cro
ytd analysi clinicaltri gov compani
track activ close studi regist clinicaltri gov databas
locat sponsor lead investig icon plc syneo health formerli inc
research inventiv medpac parexel health scienc iqvia formerli
quintilesim covanc chiltern recent acquir labcorp/cov
follow analysi track covanc chiltern subsidiari lh well inc
research inventiv syneo health independ better analyz cro-
accord analysi labcorp covance/chiltern activ ad
trial follow parexel syneo health iqvia
icon plc medpac furthermor analysi show four
termin withdraw suspens across track note
phase safeti efficaci studi evalu lesinurad mg particip
gout renal impair suspend quarter medpac act
sponsor trial enrolle plan figur illustr
data provid addit detail respect cancel page
medpac led way enrolle per newli regist trial across lone
trial trial investig safeti efficaci lesinurad administ xoi
particip moder renal impair gout chronic kidney diseas
figur total current activ studi ct gov
cro march
figur studi termin withdrawn
suspend vs new studi regist start
note due materi lag quarterli new clinic trial registr post recent data may
captur full dataset current quarter
note due materi lag quarterli new clinic trial registr post recent data may
captur full dataset current quarter
recruitingact recruitingnot yet charl martineau pm univers toronto
figur total trial registr start across track cro
figur averag enrol newli regist trial cro
 charl martineau pm univers toronto figur total clinic trial cro list clinicaltri gov march
detail termin suspens withdraw
studi alon combin subject platinum-
resistant/refractori ovarian cancer collabor stemcentrx phase
trial enrolle time
phase safeti efficaci studi evalu lesinurad mg particip
impair medpac collabor
gout renal
pharmaceut phase trial enrolle time
studi healthi particip particip hypertens
high blood pressur health scienc collabor eli lilli phase
trial enrolle time
comparison inhal oxytocin ih intramuscular im oxytocin pregnant
women intraven iv oxytocin non-pregn women syneo
collabor glaxosmithklin phase trial enrolle
phase studi aducanumab earli alzheim diseas
emerg knowledg iqvia biogen relationship believ may
act collabor phase alzheim diseas trial well
associ phase trial cancel ad studi design evalu
aducanumab effect temper cognit function impair enrol
particip aggreg given sizeabl enrol acknowledg
potenti prolong wind-down process still revenue-gener servic
new studi start convent drug grew y/i studi registr
convent drug also grew y/i biolog registr start
volatil highlight studi start climb y/i registr
increas y/i note highlight due materi lag quarterli clinic
trial registr post relat process time ct gov websit recent
recruitingact recruitingnot yet charl martineau pm univers toronto
quarterli trend may less relev baromet current cro industri trend across
entir databas
intervent quarterli
figur histor new clinic trial start
note due materi lag quarterli new clinic trial registr post recent data may
captur full dataset current quarter
note due materi lag quarterli new clinic trial registr post recent data may
captur full dataset current quarter
figur clinic trial start therapeut
figur clinic trial start therapeut
categori skew toward oncolog
note clinic trial start includ trial relat drug develop post-approv real
world studi studi directli relat commerci develop
due materi lag quarterli new clinic trial registr post recent data may
captur full dataset current quarter
note clinic trial start includ trial relat drug develop post-approv real
world studi studi directli relat commerci develop
due materi lag quarterli new clinic trial registr post recent data may
captur full dataset current quarter
figur world-wide clinic trial geographi
figur regist clinic trial intervent
note trial may take place multipl locat therefor may repres multipl
studi total count
phase phase growthnorth south east intervent charl martineau pm univers toronto
total databas figur may give us relev insight underli demand trend given
fda law mandat clinic trial meet one follow criteria must
regist databas requir investig new drug applic ind
held least one domest clinic trial site drug biolog devic
manufactur us export research see definit detail
caveat acknowledg inher limit gener search
extens databas simpli number trial necessarili indic
quarterli report metric howev data allow us compar busi win
across competitor well track life-cycle clinic trial move
complet withdrawn suspend termin
iqvia specif caveat data collect
expect iqvia formerli quintilesim figur partial snapshot
total studi result search limit associ frequenc use
word quintil acronym trial unrel either compani curb
possibl inflat figur limit search clinic trial explicitli name
iqvia quintil im health sponsor track mention
either compani locat lead investig within categori activ
recruit yet recruit open studi
requir fdaaa clinic trial meet fda definit applic
clinic trial initi septemb on-going time must regist
submit result inform clinicaltri gov databas run nation librari
medicin nlm nation institut defin act applic
trial drug biolog clinic investig exclud phase clinic
investig drug biolog subject food drug administr fda
trial devic control trial health outcom devic subject fda
regul exclud small feasibl studi pediatr post-market surveil
requir fda
accord clinicaltrialt gov applic clinic trial gener includ intervent
studi fda-regul drug biolog devic meet one follow
criteria trial held one site us trial submit fda
investig new drug applic ind investig devic exempt
trial involv drug biolog devic manufactur us export
highlight key definit ration behind segment label classif
clinicaltri gov defin open studi trial current recruit particip
recruit particip futur classifi expand access fda
also includ studi classifi enrol invit exclud open studi
whose status unknown trial updat two year
activ recruit trial current recruit particip
expand access instanc investig new drug made avail
patient otherwis would qualifi particip on-going clinic trial
due variou health reason expand access fda allow
manufactur provid patient seriou diseas condit access
investig drug certain situat proven may benefit
enrol invit particip select specif demograph
decid research trial particip must meet specif criteria
particip invit
yet recruit trial yet start recruit
clinicaltri gov defin close studi trial longer recruit particip
end complet stop prior complet variou reason
activ recruit on-going trial longer recruit patient
complet trial end complet longer examin
termin trial stop recruit longer examin treat
patient end complet start
unknown trial statu recruit yet recruit activ recruit
whose status confirm updat within past two year
suspend trial stop recruit longer examin treat
patient end complet may start
withdrawn trial end prior recruit first particip
defin activ studi clinic trial revenu gener revenu
gener futur includ aforement studi categor
activ recruit yet recruit activ recruit
new regist trial defin studi first submit clinicaltri gov
registr given time period submit databas registr
studi inform offici avail public
clinic trial start defin studi enrol period began
life scienc tool diagnost
price month
rais tp across cro univers
rais tp reiter outperform
light construct
clinicaltri gov datapoint conjunct upbeat biotech commentari
industri constitu biotech fund data mix despit
govern shutdown headwind rais target price syneo
risk call includ tighten biotech
fund demand shift cancel integr headwind
valuat metric
number share
 close
price apr rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
global contract research organ cro oper
clinic drug develop commerci market
follow merger inventiv health second largest
cro largest contract commerci organ
blue sky scenario assum continu
industri lead growth sustain rel superior profit
larg pharma client sizabl project award lower
expect cancel continu strength spend
outsourc demand cross-sel opportun relat
merger inventiv health aug
grey sky scenario assum deceler
growth declin profit trajectori share loss weaken
demand small/mid-s biotech custom increas
cancel custom consolid headwind relat
inventiv integr slowdown spend
 close
life scienc tool diagnost
rais tp across cro univers
rais tp reiter outperform
light construct
clinicaltri gov datapoint conjunct upbeat biotech commentari
industri constitu biotech fund data mix despit
govern shutdown headwind rais target price iqvia
risk call includ tighten biotech fund
 demand shift cancel integr headwind
price month
valuat metric
number share
 close
price apr rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
iqvia inc world largest contract research organ
cro lead healthcar inform technolog servic
blue sky scenario support bull
sotp scenario assum cost synergi im merger
exceed expect substanti cross sell cro
commerci servic exist new client greater new project
award due broader diversifi servic offer
pronounc strength spend fundament outsourc
grey sky scenario support bear
sotp scenario assum cost synergi take longer
expect captur integration-rel miscu includ
disrupt servic client capit deploy misstep
weaken demand outsourc relev
 close
life scienc tool diagnost
rais tp across cro univers
rais tp reiter neutral light construct clinicaltri gov
datapoint conjunct upbeat biotech commentari industri
constitu biotech fund data mix despit
govern shutdown headwind rais target price charl river
risk call includ tighten biotech fund
 demand shift cancel integr headwind
price month
valuat metric
number share
 close
price apr rate neutral target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
charl river laboratori intern inc full servic earli
model research develop new drug devic
blue sky scenario assum continu
robust industri trend expedit pronounc synergi
recent acquisit near term acceler larg pharma
biotech demand consist price increas identif
greater margin expans opportun continu market share
grey sky scenario assum oper
disrupt miscu recent acquisit weak
pressur increas insourc competit
 close
life scienc tool diagnost
rais tp across cro univers
rais tp reiter outperform
light construct
clinicaltri gov datapoint conjunct upbeat biotech commentari
industri constitu biotech fund data mix despit
govern shutdown headwind rais target price medpac
risk call includ tighten biotech fund
price month
valuat metric
number share
 close
price apr rate outperform target price analyst erin wright
profit tax
chang work capit
oper
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
medpac full-servic therapeutically-focus contract
servic biopharmaceut medic devic industri
blue sky valuat assum signific
acceler organ sale growth healthi fund environ
increas profit success new servic offer
substanti new busi win continu strong outsourc
demand small/mid-s biotech custom
grey sky valuat assum deceler
sale growth declin profit weaken demand
small/mid-s biotech custom custom consolid
slowdown overal spend
 close
life scienc tool diagnost
price month
rais tp across cro univers
rais tp reiter outperform
light construct
clinicaltri gov datapoint conjunct upbeat biotech commentari
industri constitu biotech fund data mix despit
govern shutdown headwind rais target price icon
risk call includ tighten biotech fund
 demand shift cancel integr headwind
valuat metric
number share
 close
price apr rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
icon public limit compani icon ireland-bas contract
servic pharmaceut biotechnolog medic devic
blue sky scenario iclr assum substanti
new busi win addit project award offset
sizabl cancel increment profit margin expans
pronounc strength spend outsourc demand
grey sky scenario iclr assum greater-than-
expect declin busi largest custom increas
consolid capit deploy misstep weaken demand
outsourc
 close
life scienc tool diagnost
rais tp across cro univers
rais tp reiter outperform
light construct
clinicaltri gov datapoint conjunct upbeat biotech commentari
industri constitu biotech fund data mix despit
govern shutdown headwind rais target price
risk call includ tighten biotech fund
price month
valuat metric
number share
 close
price apr rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
inc contract research organ
servic biotechnolog pharmaceut industri
blue sky scenario assum meaning
acceler profit margin nt faster materi near term
revenu gener recent award addit strateg
partnership predic continu healthi industri dynam
deceler profit margin less revenu gener recent
award expect project cancel client loss custom
consolid slowdown outsourc demand
 close
life scienc tool diagnost
labcorp america lh
rais tp across cro univers
rais tp reiter outperform
light construct
clinicaltri gov datapoint conjunct upbeat biotech commentari
industri constitu biotech fund data mix despit
govern shutdown headwind rais target price labcorp
risk call includ tighten biotech fund
 demand shift cancel integr headwind
price month
valuat metric
number share
 close
labcorp america lh
price apr rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
labcorp provid diagnost test inform servic
better fundament perform sentiment could drive upsid
target price blue sky scenario lh
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
lh
 close
compani mention price
labcorp america lh outperform tp
erin wilson wright certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
